C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S21, 2014 Special supplement with the abstract book of LATINFARMA 2013 Conference C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY Castañeda G. Departamento de Farmacología. Centro de investigación y de Estudios Avanzados del Instituto Politécnico Nacional. Av. Instituto Politécnico Nacional 2508, 07360 México, D.F. Abstract Spinal cord injury … Continue reading C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY

J Pharm Pharmacogn Res 2(Suppl. 1): S21, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 005: PHARMACOKINETIC CHANGES INDUCED BY SPINAL CORD INJURY

Castañeda G.

Departamento de Farmacología. Centro de investigación y de Estudios Avanzados del Instituto Politécnico Nacional. Av. Instituto Politécnico Nacional 2508, 07360 México, D.F.
Abstract

Spinal cord injury (SCI) is a life-threatening event that not only results in a sensory-motor loss below the site of lesion, but also causes autonomic alterations including gastrointestinal and hemodynamic changes. These changes are known to modify drug availability. Significant changes in drug absorption, volume of distribution and clearance have been reported in patients after cord lesion and it has been suggested that these changes could have an impact on the efficacy and safety of a variety of drugs in this population. Characterization of the physiopathological alterations underlying pharmacokinetic changes that occur in patients with SCI has been complicated because of the important variability induced by differences in injury characteristics, as well as in the individual conditions of each patient. Moreover, not all drugs exhibit altered disposition after SCI. Therefore, depending on which physiological mechanisms are involved in the absorption, distribution and elimination of a given drug, SCI will or will not change its pharmacokinetic parameters. There is evidence suggesting that the magnitude of the pharmacokinetic changes will depend on variables related to the injury itself: site of injury, intensity and the time elapsed after lesion. However, at present we do not have enough information to propose a rational strategy for drug dosing in patients with spinal cord injury. Doses are selected on empirical bases, often resulting in therapeutic failure. Thus, systematic research is required to fully elucidate this issue. Hence, our group has used animal models, where the lesion can be standardized, to characterize and understand the impact of spinal cord injury on drug disposition.

Toxicity evaluation of Ruta angustifolia leaves ethanolic extract
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 437-447, May-June 2023. DOI: https://doi.org/10.56499/jppres23.1609_11.3.437 Original Article Acute and repeated dose 28-day oral toxicity of Ruta angustifolia Pers. leaves ethanolic extract in Wistar rats [Toxicidad oral aguda y por dosis repetidas durante 28 días del extracto etanólico de hojas de Ruta angustifolia Pers. en ratas Wistar] Tutik … Continue reading Toxicity evaluation of Ruta angustifolia leaves ethanolic extract
Adolescents in Indonesia and COVID-19 pandemic
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 426-436, May-June 2023. DOI: https://doi.org/10.56499/jppres22.1560_11.3.426 Original Article Perception, mental health, and social media exposure on adolescents in Indonesia during COVID-19 pandemic [Percepción, salud mental y exposición a los medios sociales en adolescentes de Indonesia durante la pandemia de COVID-19] Efa Nugroho1*, Alfiana Ainun Nisa1, Widya Hary Cahyati1, … Continue reading Adolescents in Indonesia and COVID-19 pandemic
Decaffeinated green tea and coffee extracts and metabolic syndrome
J. Pharm. Pharmacogn. Res., vol. 11, no. 3, pp. 414-425, May-June 2023. DOI: https://doi.org/10.56499/jppres23.1593_11.3.414 Original Article Decaffeinated green tea and green coffee extracts as metformin’s add-on enhance metabolic syndrome risk factors and improve the cardiac insulin-gene-related pathway [Extractos de té verde y café verde descafeinados como complemento de la metformina mejoran los factores de riesgo del … Continue reading Decaffeinated green tea and coffee extracts and metabolic syndrome

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio